The objective is to develop an efficient technological solution for the diagnosis of intracranial pressure (ICP).
What is intracranial pressure?
Intracranial pressure is an increasing pressure inside the skull that usually results from a brain injury or other medical condition. Brain injuries in general are notoriously complicated to detect and ICP is usually diagnosed by a lumbar puncture, a procedure that is both invasive and expensive.
As a result, the opportunity to offer a tool that easily measures changes in ICP non-invasively is key to ensuring that the right treatment decisions are made for patients.
Epipole, the retinal video imaging specialist, will contribute its portable video ophthalmoscope technology, while Statumanu will provide its AI software, capable of evaluating images of retinal blood vessels to provide instant assessment and continuous monitoring of ICP changes, to the Eurostar project, with the aim of introducing a non-invasive technology solution for the optimisation of the ICP diagnostic process.
The project will combine Epipole’s epiCam technology, which allows clinicians to scan the retina using real-time video and extract high-quality images, with Statumanu’s AI software that will capture the retinal data needed by the software to make the diagnosis.
Speaking about this promising initiative, Jakob Find Madsen, founder and CEO of Statumanu ICP, explained how Epipole is the ideal partner to make this innovative solution a success. Indeed, following a thorough review of all retinal cameras available on the market, it was concluded that the lightweight, portable camera, which also allows for high-resolution video, was the ideal match for the integration.
For his part, Dr. Craig Robertson, Epipole’s founder and CEO, said the company was delighted to have secured Eurostars funding for this promising collaboration with Statumanu. Epipole looks forward to helping transform the way intracranial pressure is diagnosed to support better clinical decision making and ultimately improve patient outcomes, he concluded.
Once the technology integration is completed, a clinical study to evaluate the performance of the solution will be conducted at the University of Southern Denmark.